A 35-year-old female with schizoaffective disorder has been taking olanzapine 15 mg nightly for six months with excellent psychiatric symptom control. At her monitoring visit, the PMHNP reviews the following changes since starting olanzapine: weight gain of 22 pounds (current BMI 31.2, baseline BMI 27.4), fasting glucose 118 mg/dL (baseline 92 mg/dL), triglycerides 210 mg/dL (baseline 145 mg/dL), HDL cholesterol 38 mg/dL (baseline 48 mg/dL), and blood pressure 128/82 mmHg (baseline 118/76 mmHg). The patient is psychiatrically stable and expresses reluctance to change medications. The PMHNP is evaluating the metabolic impact of the current treatment regimen. Which evaluation is most appropriate?